March 25 (Reuters) - Denali Therapeutics Inc DNLI.O:
DENALI THERAPEUTICS ANNOUNCES U.S. FDA APPROVAL OF AVLAYAH™ (TIVIDENOFUSP ALFA-EKNM) FOR TREATMENT OF HUNTER SYNDROME (MPS II)
DENALI THERAPEUTICS INC - AVLAYAH TO BE AVAILABLE IN U.S. SHORTLY AFTER APPROVAL, ADMINISTERED ONCE WEEKLY
DENALI THERAPEUTICS INC - AWARDED RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER WITH FDA APPROVAL